TuesdayJul 02, 2024 10:08 am

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Releases Significant Findings from Phase 3 Parkinson’s Study, Schedules Webcast

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting new data from its phase 3 PD study. According to the report, study findings indicate that buntanetap, the company’s proprietary drug candidate, is safe and effective in improving motor and nonmotor activities and improving cognitive functions in patients with early Parkinson’s disease. Specifically, buntanetap stopped cognitive decline in all enrolled patients and improved cognition in patients with mild dementia, improved motor and nonmotor PD-related functions in patients with a diagnosis of more than three years,…

Continue Reading

MondayJul 01, 2024 2:00 pm

BioMedNewsBreaks — PaxMedica Inc. (PXMD) Intensifying Efforts to Achieve Significant Program Milestones

PaxMedica (OTC: PXMD), a biopharmaceutical company specializing in neurological disorders, is preparing to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for using suramin to treat Human African Trypanosomiasis (“HAT”), a well-established treatment in East Africa for nearly a century. A recent article discussed PaxMedica gearing up for a significant Type C meeting it had with the FDA, which “is critical for the advancement of PAX-101, the company’s leading drug candidate for treating autism, as it progresses through the regulatory framework… For PaxMedica, this Type C meeting is a strategic opportunity to engage with…

Continue Reading

MondayJul 01, 2024 12:13 pm

BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Retains Digital Marketing Platform to Increase Market Awareness

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announced that it has partnered with Totaligent Inc. (OTC: TGNT) to assist the company in its efforts to enhance its market awareness. According to the announcement, FSD Pharma retained the services of Totaligent with an objective to “foster productive, continuing dialogues with shareholders and other market participants.” Totaligent brings more than two decades of experience in market-awareness campaigns to the table; the company also has a database of 32 million active investors, which it communicates with through email,…

Continue Reading

MondayJul 01, 2024 11:45 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Now Listed on Russell Microcap Index

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has been added to the Russell Microcap(R) Index. The move was effective after market close on June 28, 2024, and is part of FTSE Russell’s annual reconstitution. According to the announcement, the annual Russell U.S. Indexes represent the 4,000 largest U.S. stocks as of April 30, 2024; the index ranks the stocks by total market capitalization. HeartBeam will retain its listing on the index for one year and will also be included in either the U.S. large-cap Russell 1000(R) Index or small-cap…

Continue Reading

FridayJun 28, 2024 12:38 pm

BioMedNewsBreaks — VolitionRx Limited (NYSE American: VNRX) Highlights Latest Achievements in Mid-Year Review

  VolitionRx Limited (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company focused on saving lives and improving outcomes for people and animals with life-altering diseases, has released a mid-year review that highlights significant milestones, such as the expansion of the Nu.Q(R) Vet Cancer Test, which is now available for purchase in 15 countries. Additionally, Volition is engaged in active commercial discussions with significant players in the fields of liquid biopsy and in vitro diagnostics (“IVD”), for sepsis, and oncology. Cameron Reynolds, President and Group Chief Executive Officer of Volition, emphasized the successful support provided to veterinary licensing and distribution partners…

Continue Reading

ThursdayJun 27, 2024 3:44 pm

BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Notes ‘Important Step’ as Phase 1 Lucid-21-302 Trial Receives HREC Approval

  FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has received a key approval for its planned Lucid-21-302 trial. According to the announcement, the human ethics review committee (“HREC”) in Australia approved the trial, which is titled “A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants.” A first-in-class, nonimmunomodulatory, neuroprotective compound, Lucid-21-302 offers a unique mechanism of action for the treatment of multiple sclerosis (“MS”). “After much…

Continue Reading

ThursdayJun 27, 2024 9:35 am

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Filing of Provisional Patent Covering Manufacturing Process of New Solid Forms of Buntanetap

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), is announcing the filing of a provisional patent. This patent covers the manufacturing process of new solid forms of buntanetap (formerly known as Posiphen or ANVS401), which targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins. According to the announcement, the patent encompasses the methods for manufacturing the new crystalline form of buntanetap (CAS# 3032752-92-1) as well as the entire synthesis process, from basic starting materials to finished (>99.9% pure) GMP product, suitable for manufacturing scale at ton…

Continue Reading

WednesdayJun 26, 2024 3:01 pm

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Pricing of Registered Direct, Concurrent Private Placement

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced its entry into securities purchase agreements with health-care focused institutional investors for the purchase and sale of 568,000 shares of common stock in a registered direct offering and warrants to purchase up to 568,000 shares of common stock in a concurrent private placement (together with the registered direct offering, the “offering”) at a combined purchase price of $2.45 per share. The warrants issued per the concurrent private placement will…

Continue Reading

WednesdayJun 26, 2024 2:40 pm

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Submits Patent Application for New Composition of Buntanetap Matter

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), has filed a patent with the U.S. Patent and Trademark Office. The patent covers novel solid forms of buntanetap, selecting the best crystal and building upon the provisional patent the company filed in June 2023. Formerly known as posiphen or ANVS401, buntanetap targets neurodegeneration by hindering the formation of multiple neurotoxic proteins connected with disease, including amyloid beta, tau, alpha-synuclein and TDP43. Through this process, buntanetap has the potential to reverse neurodegeneration in Alzheimer’s, Parkinson’s and other…

Continue Reading

WednesdayJun 26, 2024 2:13 pm

BioMedNewsBreaks — HealthLynked Corp. (HLYK) Announces New COO, Appoints Seasoned Veteran to Enhance Operations and Drive Initiatives

  HealthLynked (OTCQB: HLYK), a leading provider of healthcare technology solutions, has announced a new chief operating officer. According to the announcement, the company has promoted Bill Crupi to the position, effective immediately. Crupi joined the company last year and has been instrumental in optimizing operational efficiencies and supporting the company's growth trajectory. Crupi has more than 20 years’ experience working in the healthcare industry and has served in several operational management leadership roles. In his new role, Crupi will manage the daily operations of HealthLynked, with a specific focus on enhancing operational efficiencies, driving strategic initiatives and ensuring the…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050